Novo Nordisk’s recent upgrade to a Buy rating centers on its FDA-approved oral Wegovy pill, which analysts view as the primary catalyst to reignite the company’s growth trajectory and recapture market share in the GLP-1 space. While pricing pressures on weight-management therapies and potential cannibalization of injectables from the new oral format present challenges, Novo Nordisk is leveraging an aggressive global distribution network and stringent cost management initiatives to limit margin erosion. Competition from peers such as Eli Lilly has intensified, but management forecasts that strong patient retention rates and streamlined manufacturing partnerships will drive upside surprises in quarterly volume metrics throughout 2026.

Despite expectations of a modest 2% revenue decline in 2026 driven by pricing headwinds and product mix shifts, Novo Nordisk maintains industry-leading operating efficiency with EBITDA margins exceeding 47%. Following its acquisition of Catalent’s active pharmaceutical ingredient business, the company anticipates generating more than $10 billion in free cash flow annually, supporting continued investment in R&D, shareholder distributions, and potential bolt-on acquisitions. This cash-rich profile underpins Novo Nordisk’s strategic flexibility and appeals to investors focused on durable cash returns amid a competitive biopharma landscape.